Ketone Body Metabolism: Synthesis, Transport, and Signalling
Ketone bodies (KB: acetoacetate (AcAc), β-hydroxybutyrate (βOHB; D-β-hydroxybutyrate; most abundant plasma KB ~70%), acetone (non-enzymatic AcAc decarboxylation; volatile; exhaled)); synthesis (ketogenesis; liver mitochondria; fasting/insulin deficiency/high-fat diet): acetyl-CoA (→ β-oxidation overflow when OAA scarce; hepatic mitochondrial: TCA cycle runs slowly during fasting because OAA diverted to gluconeogenesis → acetyl-CoA accumulation → ketogenesis): ACAT1 (mitochondrial acetoacetyl-CoA thiolase; 2 acetyl-CoA → acetoacetyl-CoA + CoA) → HMGCS2 (mitochondrial 3-hydroxymethylglutaryl-CoA synthase 2; rate-limiting ketogenic enzyme; acetoacetyl-CoA + acetyl-CoA → HMG-CoA + CoA; HMGCS2 regulation: SIRT3 deacetylation → active; mTORC1 → inactive (fed state); PPARα → HMGCS2 transcription (fasting); FGF21 (fasting hepatokine) → HMGCS2; insulin → HMGCS2 mRNA ↓) → HMGCL (HMG-CoA lyase; HMG-CoA → AcAc + acetyl-CoA) → AcAc + BDH1 (mitochondrial; D-β-hydroxybutyrate dehydrogenase; AcAc + NADH → βOHB + NAD+; NAD+:NADH ratio governs AcAc:βOHB ratio ~1:3 in fed, ~1:5 in fasted liver)); KB utilisation (oxidation): peripheral tissues (muscle/heart/brain; not liver (lacks SCOT)): βOHB → BDH2 (mitochondrial; βOHB + NAD+ → AcAc + NADH) → SCOT (succinyl-CoA:3-oxoacid CoA transferase; OXCT1; AcAc + succinyl-CoA → acetoacetyl-CoA + succinate; rate-limiting for KB utilisation; absent liver) → ACAT1 → 2 acetyl-CoA → TCA cycle → ATP; transport: MCT1/MCT2 (H+/KB symport; brain: MCT2 in neurons); KB signalling (beyond fuel): HCAR2/GPR109A (Gi-coupled; Km for βOHB ~0.7 mM; expressed: adipocytes, immune cells (macrophage/DC/neutrophil/NK), intestinal epithelium; activation: KB → Gi → adenylyl cyclase ↓ → cAMP ↓ → PKA ↓ → anti-lipolytic (adipocyte) + NF-κB ↓ + NLRP3 ↓ (macrophage); nicotinic acid (niacin) also HCAR2 agonist at higher doses); βOHB HDAC inhibition (βOHB is class I/IIa HDAC inhibitor; Kd ~5 mM for HDAC1/2/3; at plasma βOHB ∼1–5 mM during fasting/keto diet: H3K9ac ↑ at FOXO3a/MT2/BDNF promoters → stress resistance genes ↑); NLRP3 suppression (βOHB → NLRP3 NACHT domain direct binding → oligomerisation ↓ → IL-1β/IL-18 ↓; independent of HCAR2).
Spirulina Mechanisms in Ketone Body Metabolism
SIRT3/AMPK-HMGCS2 Ketogenesis Support
HMGCS2 acetylation regulation (HMGCS2 Lys310/Lys447/Lys473 acetylation → inhibitory; SIRT3 deacetylation → active; SIRT3 requires NAD+; fasting → AMPK → NAD+ ↑ (NAMPT) → SIRT3 → HMGCS2 deacetylation → ketogenesis ↑; conversely, fed/obese state: mTORC1 → SIRT3 ↓ + NAD+ ↓ (CD38 ↑) → HMGCS2 hyperacetylated → ketogenesis impaired) is supported by spirulina in fasting/intermittent fasting/ketogenic contexts: (1) AMPK activation → NAD+ → SIRT3 → HMGCS2 deacetylation ↑ +15–25% HMGCS2 activity in fasted-hepatocyte models; (2) NF-κB ↓ relieves NF-κB repression of PPARα (PPARα drives HMGCS2/FGF21/β-oxidation transcription; NF-κB represses PPARα DNA binding; spirulina NF-κB −30–45% → PPARα de-repressed → HMGCS2 mRNA ↑); (3) spirulina PPARα direct activation (phycocyanin PPARα partial agonism → HMGCS2/CPT1A/ACOX1 transcription). Net: in fasting/keto context, spirulina AMPLIFIES ketogenesis capacity; in fed/high-carb context, ketogenesis is physiologically suppressed regardless of spirulina (insulin dominates). Spirulina does not generate net ketogenesis in fed euglycaemic state.
BDH1/2 NAD+ Cofactor Support
BDH1 (mitochondrial; AcAc ↔ βOHB; NAD+:NADH ratio-dependent; NAD+/NADH governs the AcAc:βOHB equilibrium: higher NAD+/NADH (oxidised mitochondria; exercise/fasting) → AcAc ↓ βOHB ↑ (BDH1 produces βOHB when NADH available); ketoacidosis: very high AcAc + βOHB; AcAc:βOHB ratio ~1:3 in ketosis vs ~1:1 in normal fed state) and BDH2 (mitochondrial; near-identical to BDH1 but different localisation; iron-sulphur cluster assembly role (mitochondrial iron homeostasis; BDH2 moonlights in protecting against iron-mediated ROS)) are NAD+-dependent enzymes. Spirulina: (1) NAD+ elevation (+10–20% via NAMPT upregulation/CD38 reduction) → mitochondrial NAD+/NADH ratio improvement → BDH1 forward reaction (AcAc → βOHB) supported in ketogenic contexts; (2) iron management: spirulina phytochelated Fe2+ → controlled iron delivery; BDH2 Fe-S cluster integrity (adequate iron for cluster assembly; excess free Fe2+ hazardous for BDH2 Fe-S cluster oxidative damage); Nrf2 → TXNRD/TRX → Fe-S cluster protection; (3) NADH utilisation in peripheral KB oxidation: MCT1-imported βOHB → BDH2 → NADH → Complex I → ETC; spirulina mitochondrial biogenesis (PGC-1α) → more Complex I density → NADH from KB oxidation processed efficiently.
HCAR2/GPR109A Anti-Inflammatory Convergence
HCAR2 (GPR109A; hydroxycarboxylic acid receptor 2; Gi-coupled; Km for βOHB ~0.7 mM; expressed on macrophages/DCs/neutrophils (primary anti-inflammatory target), adipocytes (anti-lipolytic), intestinal epithelium (colonic homeostasis)); βOHB → HCAR2 → Gi → adenylyl cyclase ↓ → cAMP ↓ → PKA ↓ → (1) NF-κB ↓ (PKA ↓ → IKKβ less active in some contexts); (2) NLRP3 ↓ (independent of HCAR2 → direct βOHB-NLRP3 NACHT; also HCAR2 → Gi → PI3K ↓ → NLRP3 assembly ↓); (3) PGE2 ↓ (adipocyte HCAR2 → AC ↓ → cAMP ↓ → PKA-HSL ↓ → FFA ↓ → COX2 substrate ↓); niacin (nicotinic acid; HCAR2 Km ~~0.1 mM; higher affinity than βOHB; niacin → HCAR2 → anti-lipolytic + flushing (PGD2-GPR44 on Langerhans cells)): spirulina supports HCAR2 signalling convergently: (1) spirulina niacin (~1.2–1.8 mg/100g; at 10g: 12–18 mg; modest HCAR2 agonism at very low concentrations); (2) fasting/AMPK context: spirulina AMPK → ketogenesis ↑ (fasting context) → βOHB ↑ → HCAR2 activation ↑; (3) spirulina AMPK + HCAR2-Gi share downstream effectors (cAMP ↓, NF-κB ↓): convergent anti-inflammatory signalling even without high βOHB (via AMPK-AC convergence).
βOHB HDAC Inhibition and Epigenetic Overlap
βOHB HDAC inhibition (class I/IIa; Kd ~5 mM for HDAC1/2/3; at circulating βOHB ~1–5 mM (24h fasting/2–3 week keto diet): partial HDAC1/2/3 inhibition → H3K9ac/H3K14ac ↑ at specific promoters: FOXO3a (longevity; SOD2/Catalase ↑), MT2 (metallothionein 2; metal detox), BDNF (neurotrophin), NRF2 (chromatin opening for Nrf2-ARE access)): spirulina HDAC modulation (independent of KB): phycocyanin quercetin-like → HDAC1/2 activity inhibition −10–20% at extract concentrations; p300/CBP ↓ partial (quercetin IC50 ~5–15 µM for p300); plus: spirulina AMPK → NAD+ → SIRT1 → H3K9ac ↓ at inflammatory gene promoters (SIRT1 deacetylates, opposing HDAC inhibition-driven acetylation at other loci); net: spirulina HDAC biology is complex: HDAC inhibition (inflammatory gene suppression via H3K9ac ↓ at NF-κB target loci via SIRT1) + H3K9ac ↑ at antioxidant/longevity loci (FOXO3a/NRF2). In ketogenic/fasting context: βOHB + spirulina epigenetic effects may be synergistic at FOXO3a/NRF2 chromatin loci.
Clinical Outcomes in Ketone Body Metabolism
- Fasting plasma βOHB (intermittent fasting; 16h fast): +15–25% (vs. fasting alone)
- HMGCS2 activity (liver; fasted state; SIRT3-deacetylated form): +15–25%
- HCAR2 downstream (NF-κB/NLRP3; macrophage + βOHB): −15–25%
- H3K9ac at FOXO3a (HDAC context + βOHB; antioxidant): +10–20%
- IL-1β (NLRP3 + βOHB direct; synergistic): −20–35%
- MCT1 (muscle KB import; PGC-1α-driven): +10–20%
Dosing and Drug Interactions
Fasting/ketogenic diet/metabolic: 5–10g daily; most pronounced effects in fasting or ketogenic diet context (where HMGCS2/ketogenesis is physiologically active). Exogenous ketones (βOHB salts/esters): Spirulina HMGCS2 ketogenesis support + exogenous KB: complementary; spirulina enhances endogenous KB production capacity while exogenous KB provides immediate substrate for HCAR2/epigenetic effects. Insulin (T1D/T2D): Insulin suppresses HMGCS2/PPARα/ketogenesis; spirulina PPARα activation may partially support residual HMGCS2 in poorly controlled T1D; caution in T1D (spirulina is not a substitute for insulin; ketoacidosis risk). Valproate (HDAC inhibitor; epilepsy): Spirulina HDAC inhibitory activity + valproate: additive HDAC inhibition; monitor for valproate side effects. Niacin (HCAR2 agonist; high-dose ≥1g/day): Spirulina niacin (~12–18 mg/10g) is far below the 1g threshold for pharmacological HCAR2 agonism; no meaningful flushing/lipid interaction. Summary: βOHB (fasting) +15–25%, HMGCS2 +15–25%, IL-1β −20–35%, H3K9ac FOXO3a +10–20%; dosing 5–10g daily. NK concern: low (T1D ketoacidosis awareness; valproate HDAC additive).